IgG4-related kidney disease: treatment standard

Clicks: 16
ID: 331936
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #117 of 152 articles by views in nephrology dialysis transplantation

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 152 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
IgG4-related disease is a systemic, immune-mediated, fibro-inflammatory condition that can affect virtually any organ. IgG4-related kidney disease represents one of the most clinically relevant manifestations and encompasses a spectrum of renal manifestations, including IgG4-related tubulointerstitial nephritis, membranous nephropathy, and obstructive uropathy secondary to retroperitoneal fibrosis. The diagnosis remains challenging and requires integration of clinical and laboratory findings, along with imaging, and histopathology, as no single biomarker is sufficiently sensitive or specific. Although systemic immunosuppressive therapies largely overlap across manifestations, the practical management differs substantially between parenchymal kidney disease and retroperitoneal fibrosis, particularly with regard to mechanisms of kidney injury, the need for interventional procedures, treatment goals, and monitoring strategies. Glucocorticoids are the cornerstone of induction therapy and typically provide rapid clinical responses; however, the chronic-relapsing course of IgG4-related disease and the burden of glucocorticoid-related toxicity have prompted investigation in steroid-sparing strategies. Conventional immunosuppressive agents have been used with controversial results, whereas B-cell-targeting therapies, particularly rituximab, have demonstrated high efficacy in both induction and maintenance settings. Management should ultimately be individualised, taking into account the pattern of renal involvement, organ dysfunction, and likelihood of reversibility. In patients with obstructive uropathy due to retroperitoneal fibrosis, interventional procedures may be required alongside immunosuppressive therapy. Long-term monitoring is essential because of the relapsing nature of the disease and the potential for chronic kidney disease. This Treatment Standard provides a practical, nephrology-oriented framework for the diagnosis, treatment and follow-up of IgG4-related kidney disease, integrating current evidence with emerging insights from immunopathogenesis and clinical trials.
Reference Key
openalex_W7221192647 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Francesco Peyronel, Giulia Palazzini, Riccardo Campi, Salvatore Granata, Lorenzo Masieri, Augusto Vaglio
Are you one of these authors? Claim your profile
Journal nephrology dialysis transplantation
Year 2026
DOI
10.1093/ndt/gfag235
URL
https://doi.org/10.1093/ndt/gfag235
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.